ASPHF Stock Financial Analysis - Ascentage Pharma Group International (OTCPK) Stock

Overview

Ascentage Pharma Group International, based in China, is a biopharmaceutical company focused on developing innovative small molecule therapies. It primarily operates in the oncology sector, with a notable emphasis on apoptosis-targeted drug development. The company has a robust pipeline featuring several key projects, most notably its series of novel Bcl-2 inhibitors designed to prompt cancer cell death, and IAP inhibitors that suppress cancer growth pathways. Additionally, Ascentage Pharma is actively advancing drug candidates targeting the protein-protein interaction and the tyrosine kinase receptor pathways. These pioneering projects underscore the company's strategic commitment to addressing unmet medical needs in the treatment of cancers and other serious diseases.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The revenue for Ascentage Pharma Group International as of June 30, 2025 is 390.60 MM.
The operating income for Ascentage Pharma Group International as of June 30, 2025 is -1,120.77 MM.
The net income for Ascentage Pharma Group International as of June 30, 2025 is -1,159.20 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30	390.60	-1,120.77	-1,159.20
2025-03-31	685.63	-749.79	-782.32
2024-12-31	980.65	-378.80	-405.43
2024-09-30	941.84	-361.44	-382.86
2024-06-30	903.03	-344.08	-360.29
2024-03-31	562.51	-618.04	-642.96
2023-12-31	221.98	-891.99	-925.64
2023-09-30	239.32	-865.49	-902.09
2023-06-30	256.65	-838.98	-878.54
2023-03-31	233.18	-861.19	-880.73
2022-12-31	209.71	-883.41	-882.92
2022-09-30	160.21	-919.62	-847.70
2022-06-30	110.71	-955.84	-812.48
2022-03-31	69.31	-944.50	-797.45
2021-12-31	27.91	-933.17	-782.42
2021-09-30	25.36	-844.37	-758.77
2021-06-30	22.80	-755.58	-735.11
2021-03-31	17.63	-720.00	-706.36
2020-12-31	12.45	-684.43	-677.61
2020-09-30	13.63	-674.81	-922.09
2020-06-30
2020-03-31

Income Statement: EPS

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30	-1.24	-1.23
2024-03-31	-2.24	-2.24
2023-12-31	-3.28
2023-09-30	-3.27	-3.27
2023-06-30	-3.26	-3.27
2023-03-31	-3.31	-3.31
2022-12-31	-3.35
2022-09-30	-3.22	-3.22
2022-06-30	-3.09	-3.09
2022-03-31	-3.08	-3.08
2021-12-31	-3.07
2021-09-30	-3.10	-3.10
2021-06-30	-3.13	-3.13
2021-03-31	-3.13	-3.13
2020-12-31	-3.14
2020-09-30	-4.75	-4.75
2020-06-30	-6.76	-6.76
2020-03-31	-9.15	-9.15

Cash Flow: Operations, Investing, Financing

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30
2025-03-31
2024-12-31	-111.36	-362.04	314.77
2024-09-30	-411.68	-203.31	312.39
2024-06-30	-712.00	-44.58	310.02
2024-03-31	-719.04	-11.33	339.39
2023-12-31	-726.08	21.92	368.75
2023-09-30	-706.63	-142.43	497.95
2023-06-30	-687.18	-306.79	627.14
2023-03-31	-670.55	-345.70	623.21
2022-12-31	-653.91	-384.61	619.27
2022-09-30	-620.11	5.37	886.00
2022-06-30	-586.30	395.35	1,152.74
2022-03-31	-595.49	-35.59	1,467.06
2021-12-31	-604.68	-466.52	1,781.39
2021-09-30	-634.80	-685.70	1,852.21
2021-06-30	-664.91	-904.89	1,923.03
2021-03-31	-637.43	-506.13	1,481.52
2020-12-31	-609.96	-107.37	1,040.00
2020-09-30	-575.85	-239.17	809.34
2020-06-30
2020-03-31

Valuation Metrics : PE, PriceToBook, PriceToTBV

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31

Management Effectiveness

The roa for Ascentage Pharma Group International as of June 30, 2025 is -0.13.
The roe for Ascentage Pharma Group International as of June 30, 2025 is -0.52.
The roic for Ascentage Pharma Group International as of June 30, 2025 is -0.21.
The croic for Ascentage Pharma Group International as of June 30, 2025 is -0.07.
The ocroic for Ascentage Pharma Group International as of June 30, 2025 is -0.06.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	-0.13	-0.52	-0.21	-0.07	-0.06
2025-03-31	-0.13	-0.52	-0.21	0.00	0.00
2024-12-31	-0.14	-5.10	-0.15	-0.18	-0.29
2024-09-30	-0.14	-5.10	-0.15	-0.12	-0.29
2024-06-30		-1.07
2024-03-31		-2.27
2023-12-31			-9.67	-3.26
2023-09-30			-1.41	-0.48
2023-06-30		-1.00
2023-03-31		-1.00
2022-12-31
2022-09-30		0.00
2022-06-30		-0.56	-0.90
2022-03-31		0.00
2021-12-31		0.00
2021-09-30	0.00	0.00
2021-06-30	-0.66		-0.34	0.14	-0.31
2021-03-31	-0.64	-1.15	-0.33	0.14	-0.30
2020-12-31	-0.56	-0.76	-0.48	0.20	-0.43
2020-09-30	-0.77	-1.04	-0.65	-0.02	-0.41
2020-06-30	-1.09		-1.30	-0.37	-0.60
2020-03-31	-1.23		-1.47	-0.31	-0.56

Gross Margins

The gross margin for Ascentage Pharma Group International as of June 30, 2025 is 0.97.
The net margin for Ascentage Pharma Group International as of June 30, 2025 is -0.41.
The operating margin for Ascentage Pharma Group International as of June 30, 2025 is -0.39.

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30	0.97	-0.41	-0.39
2025-03-31	0.97	-0.41	-0.39
2024-12-31	0.97	-0.40	-0.38
2024-09-30	0.97	-0.40	-0.38
2024-06-30
2024-03-31
2023-12-31
2023-09-30		-3.42	-3.27
2023-06-30		-3.42	-3.27
2023-03-31		-3.78	-3.69
2022-12-31
2022-09-30
2022-06-30		-7.34	0.00
2022-03-31
2021-12-31
2021-09-30
2021-06-30	0.80	-32.24	-33.14
2021-03-31	0.82	-40.07	-40.85
2020-12-31	0.84	-54.43	-54.97
2020-09-30	0.85	-67.65	-49.51
2020-06-30	0.86	-78.77	-44.92
2020-03-31	0.86	-90.28	-43.60

HK:6855	HK$79.35
DE:36X	€8.65